AIP
AVBP icon

Ameritas Investment Partners’s ArriVent BioPharma AVBP Stock Holding History

Ameritas Investment Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.3K Hold
2,352
– – ﹤0.01% 2040
2025
Q4 		$47.3K Hold
2,352
– – ﹤0.01% 2164
2025
Q3 		$43.4K Hold
2,352
– – ﹤0.01% 2232
2025
Q2 		$51.2K Sell
2,352
-502
-18% -$10.4K ﹤0.01% 2172
2025
Q1 		$52.8K Hold
2,854
– – ﹤0.01% 2073
2024
Q4 		$76K Hold
2,854
– – ﹤0.01% 1943
2024
Q3 		$67.1K Buy
2,854
+1,873
+191% +$42.5K ﹤0.01% 2022
2024
Q2 		$18.2K Hold
981
– – ﹤0.01% 2661
2024
Q1 		$17.5K Buy
+981
New +$19.8K ﹤0.01% 2609

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameritas Investment Partners's AVBP Position: Q1 2026 in Review

Ameritas Investment Partners held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 2,352 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

Ameritas Investment Partners first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $76K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Ameritas Investment Partners held 2,352 shares of ArriVent BioPharma worth $54.3K as of Q1 2026.
  • Ameritas Investment Partners left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2040 holding.
  • Ameritas Investment Partners first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Ameritas Investment Partners's ArriVent BioPharma position peaked at $76K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.